Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cancer therapy study pulled before it even started

NCT ID NCT07152236

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to test a new cell therapy called B7H3 CAR-T for people with advanced solid tumors that have a specific marker (B7H3). The goal was to see if the treatment is safe and shrinks tumors. However, the study was withdrawn before enrolling any participants, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Started

Aug 2025

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The patient fully understands the study procedures and voluntarily signs the informed consent form. 2. Patients diagnosed with tumors that demonstrate positive B7H3 expression in tumor tissues as confirmed by immunohistochemistry (IHC). 3. Presence of at least one extracranial lesion that is measurable according to the RECIST 1.1 criteria; 4. Estimated survival duration of ≥12 weeks; 5. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤1 at baseline; 6. Recovery from prior treatment-related toxicities to a level below Grade 2. 7. Adequate hematopoietic and organ function without severe impairment; 8. Availability of suitable venous access for leukapheresis, with no contraindications to the collection of white blood cells. Exclusion Criteria: 1. Patients with a history of or currently diagnosed with other malignant tumors; 2. Presence of brain metastases or clinically significant central nervous system (CNS) disorders; 3. Prior treatment within 14 days or five half-lives (whichever is longer) before blood collection for CAR-T preparation that may interfere with lymphocyte expansion; 4. HIV+,HBV,HCV,EBV,CMV. 5. Positive T-cell interferon-gamma release assay or sputum smear for tuberculosis; 6. Documented history or current evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonitis, or significant pulmonary dysfunction; 7. History of severe allergic reactions or known hypersensitivity to any component of the investigational drugs used in the study; 8. Severe cardiovascular disease or uncontrolled refractory hypertension, unless deemed stable and non-interfering with the study by the investigator; 9. Severe hepatic or renal dysfunction, or presence of altered mental status; 10. Active autoimmune or inflammatory neurological disorders; 11. Presence of uncontrolled infections requiring systemic antibiotic, antifungal, or antiviral therapy; 12. Receipt of (attenuated) live vaccines within 4 weeks prior to screening; 13. Individuals with a history of alcohol dependence or substance abuse; 14. Pregnant or lactating women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dongguan Taixin Hospital

    Dongguan, Guangdong, 523125, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.